|
|
|
|
|
| Ferreira,Paulo Roberto Abrão; Brandão-Mello,Carlos Eduardo; Estes,Chris; Gonçales Júnior,Fernando Lopes; Coelho,Henrique Sérgio Moraes; Razavi,Homie; Cheinquer,Hugo; Wolff,Fernando Herz; Ferraz,Maria Lúcia Gomes; Pessoa,Mário Guimarães; Mendes-Correa,Maria Cássia. |
| Background: Hepatitis C virus infection is a major cause of cirrhosis; hepatocellular carcinoma; and liver transplantation. The aim of this study was to estimate hepatitis C virus disease progression and the burden of disease from a nationwide perspective.Methods: Using a model developed to forecast hepatitis C virus disease progression and the number of cases at each stage of liver disease; hepatitis C virus-infected population and associated disease progression in Brazil were quantified. The impact of two different strategies was compared: higher sustained virological response and treatment eligibility rates (1) or higher diagnosis and treatment rates associated with increased sustained virological response rates (2).Results: The number of infected... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: HCV; Disease burden; Epidemiology; Incidence; Brazil. |
| Ano: 2015 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702015000400363 |
| |
|
|
| Gonçales Jr.,Fernando Lopes; Vigani,Aline; Gonçales,Neiva; Barone,Antonio Alci; Araújo,Evaldo; Focaccia,Roberto; Oliveira,Umbeliana; Coelho,Henrique Sérgio Morais; Paixao,Jacqueline; Perez,Renata; Lobato,Cirley; Weirich,Judith; Rosa,Heitor; Borges,Andrelina; Vila,Ricardo; Corrêa-Giannella,Maria Lúcia; Ferraz,Maria Lúcia Gomes. |
| Combination therapy with pegylated interferon and ribavirin is considered the new standard therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment with weight-based peginterferon alpha-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48 weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin) patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was 54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was significantly higher in patients with the non-1 genotype (67%)... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C; Interferon alpha-2b; Therapy. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000500002 |
| |
|
|
|
